Pacira BioSciences, Inc.

PCRX Healthcare Drug Manufacturers Specialty & Generic

Pacira BioSciences, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $726.4 million, up 3.63% from fiscal 2024. In the quarter to June 2026, revenue grew 6.24%, EPS grew 209.1%, free cash flow grew 502.5% and total debt fell 37.4%, each against the same quarter a year earlier. Revenue growth for ten consecutive years.

36.35 0.02 +0.06%
Market cap
$1.5B
P/E
104×
Fwd P/E
33.7×
Dividend yield
—
F-score
8/9
Altman Z
2.02
Beneish M
−2.93
Dividend safety
n/a
Older periods Sep '25 Dec '25 Mar '26 Jun '26
P/E ratio

+8 more quarters

56.02 172.53 188.33 72.49
P/S ratio
1.58 1.59 1.24 1.34
P/FCF ratio
9.14 8.44 6.89 5.58
P/Operating CF
18.66 26.40 35.61 17.42
P/B ratio
1.56 1.66 1.40 1.49
EV/Sales
2.05 2.05 1.74 1.76
EV/EBITDA
11.44 13.76 11.21 12.77
EV/FCF
11.82 10.90 9.66 7.33
Current Ratio
5.26 4.54 4.73 5.04
Net Debt/EBITDA
4.65 6.92 5.86 4.10
Debt/Equity
0.52 0.54 0.56 0.54
Earnings Yield
1.79% 0.58% 0.53% 1.38%
Free Cash Flow Yield
10.94% 11.85% 14.51% 17.93%
Free Cash Flow per Share
1.29 0.98 0.57 1.42
Book value per Share
16.51 15.55 16.16 17.03
Free Cash Flow
56.96 43.47 22.96 56.12
EV/EBIT
35.32 77.62 53.20 66.21
Other line items

Show all line items

Columns are period end dates